P53 and Beta-catenin Expression in Gallbladder Tissues and Correlation with Tumor Progression in Gallbladder Cancer

Overview

Journal Saudi J Gastroenterol

Specialty Gastroenterology

Date 2013 Jan 16

PMID 23319036

Citations 18

Authors

Mila Ghosh

Puja Sakhuja

Shivendra Singh

Anil K Agarwal

Affiliations

Soon will be listed here.

Abstract

Background/aim: The inactivation of the tumor suppressor gene and activation of the proto-oncogene are key steps in the development of human cancer. p53 and beta-catenin are examples of such genes, respectively. In the present study, our aim was to determine the role of these genes in the carcinogenesis of the gallbladder by immunohistochemistry.

Patients And Methods: Sections from paraffin-embedded blocks of surgically resected specimens of gallbladder cancer (GBC) (80 cases), chronic cholecystitis (60 cases), and control gallbladders (10 cases) were stained with the monoclonal antibody p53, and polyclonal antibody beta-catenin. Results were scored semiquantitatively and statistical analysis performed. p53 expression was scored as percentage of the nuclei stained. Beta-catenin expression was scored as type of expression-membranous, cytoplasmic, and nuclear staining. Beta-catenin expression was correlated with tumor invasiveness, differentiation, and stage.

Results: Over-expression of p53 was seen in 56.25% of GBC cases and was not seen in chronic cholecystitis or in control gallbladders. p53 expression in gallbladder cancer was significantly higher than in inflammatory or control gallbladders (P < 0.0001). p53 expression increased with increasing tumor grade (P = 0.039). Beta-catenin nuclear expression was seen in 75% cases of gallbladder cancer and in no case of chronic cholecystitis and control gallbladder. Beta-catenin nuclear expression increased with tumor depth invasiveness, and grade (P = 0.028 and P = 0.0152, respectively).

Conclusion: p53 and beta-catenin nuclear expression is significantly higher in GBC. p53 expression correlates with increasing tumor grade while beta-catenin nuclear expression correlates with tumor grade and depth of invasion, thus suggesting a role for these genes in tumor progression of GBC.

Citing Articles

Utility of IMP3, p53, and S100P immunohistochemical stains in distinguishing reactive atypia from dysplasia in cholecystectomy specimens.

Sica E, Shore K, Yang L, Phelps K, Hammer S, Gopal P Diagn Pathol. 2024; 19(1):129.

PMID: 39334193 PMC: 11429068. DOI: 10.1186/s13000-024-01550-w.

Gallbladder cancer: Progress in the Indian subcontinent.

Kumar A, Sarangi Y, Gupta A, Sharma A World J Clin Oncol. 2024; 15(6):695-716.

PMID: 38946839 PMC: 11212610. DOI: 10.5306/wjco.v15.i6.695.

Environmental and Metabolic Risk Factors Linked to Gallbladder Dysplasia.

Bojan A, Pricop C, Ciocoiu M, Vladeanu M, Bararu Bojan I, Badulescu O Metabolites. 2024; 14(5).

PMID: 38786750 PMC: 11123122. DOI: 10.3390/metabo14050273.

Next generation sequencing uncovers multiple miRNAs associated molecular targets in gallbladder cancer patients.

Saxena R, Chakrapani B, Sarath Krishnan M, Gupta A, Gupta S, Das J Sci Rep. 2023; 13(1):19101.

PMID: 37925508 PMC: 10625549. DOI: 10.1038/s41598-023-44767-3.

analysis to identify novel ceRNA regulatory axes associated with gallbladder cancer.

Saklani N, Chauhan V, Akhtar J, Upadhyay S, Sirdeshmukh R, Gautam P Front Genet. 2023; 14:1107614.

PMID: 36873948 PMC: 9978489. DOI: 10.3389/fgene.2023.1107614.

References

Ajiki T, ONOYAMA H, Yamamoto M, Asaka K, Fujimori T, Maeda S . p53 protein expression and prognosis in gallbladder carcinoma and premalignant lesions. Hepatogastroenterology. 1996; 43(9):521-6. View

Misra S, Chaturvedi A, Goel M, Mehrotra R, Sharma I, Srivastava A . Overexpression of p53 protein in gallbladder carcinoma in North India. Eur J Surg Oncol. 2000; 26(2):164-7. DOI: 10.1053/ejso.1999.0763. View

Washington K, Gottfried M . Expression of p53 in adenocarcinoma of the gallbladder and bile ducts. Liver. 1996; 16(2):99-104. DOI: 10.1111/j.1600-0676.1996.tb00712.x. View

Moon W, Park H, Lee H, Pai R, Tarnawski A, Kim K . Co-expression of cox-2, C-met and beta-catenin in cells forming invasive front of gallbladder cancer. Cancer Res Treat. 2009; 37(3):171-6. PMC: 2785404. DOI: 10.4143/crt.2005.37.3.171. View

Wee A, Teh M, Raju G . Clinical importance of p53 protein in gall bladder carcinoma and its precursor lesions. J Clin Pathol. 1994; 47(5):453-6. PMC: 502025. DOI: 10.1136/jcp.47.5.453. View

Choi Y, Xuan Y, Shin Y, Chae S, Kook M, Sung R . An immunohistochemical study of the expression of adhesion molecules in gallbladder lesions. J Histochem Cytochem. 2004; 52(5):591-601. DOI: 10.1177/002215540405200504. View

Puhalla H, Herberger B, Soleiman A, Filipits M, Laengle F, Gruenberger T . E-cadherin and beta-catenin expression in normal, inflamed and cancerous gallbladder tissue. Anticancer Res. 2005; 25(6B):4249-54. View

Roa I, Villaseca M, Araya J, Roa J, De Aretxabala X, Melo A . p53 tumour suppressor gene protein expression in early and advanced gallbladder carcinoma. Histopathology. 1997; 31(3):226-30. DOI: 10.1046/j.1365-2559.1997.2420850.x. View

Kalekou H, Miliaras D . Immunohistochemical study of microvessel density, CD44 (standard form), p53 protein and c-erbB2 in gallbladder carcinoma. J Gastroenterol Hepatol. 2004; 19(7):812-8. DOI: 10.1111/j.1440-1746.2004.03357.x. View

10.

Chaube A, Tewari M, Garbyal R, Singh U, Shukla H . Preliminary study of p53 and c-erbB-2 expression in gallbladder cancer in Indian patients manuscript id: 8962091628764582. BMC Cancer. 2006; 6:126. PMC: 1472691. DOI: 10.1186/1471-2407-6-126. View

11.

Kamel D, Paakko P, Nuorva K, Vahakangas K, Soini Y . p53 and c-erbB-2 protein expression in adenocarcinomas and epithelial dysplasias of the gall bladder. J Pathol. 1993; 170(1):67-72. DOI: 10.1002/path.1711700111. View

12.

Lee H, Lee H, Kim H, Yang H, Kim W . Tumour suppressor gene expression correlates with gastric cancer prognosis. J Pathol. 2003; 200(1):39-46. DOI: 10.1002/path.1288. View

13.

Roa I, Ibacache G, Melo A, Morales E, Villaseca M, Araya J . [Subserous gallbladder carcinoma: expression of cadherine-catenine complex]. Rev Med Chil. 2003; 130(12):1349-57. View

14.

Chang H, Jee C, Kim W . Mutation and altered expression of beta-catenin during gallbladder carcinogenesis. Am J Surg Pathol. 2002; 26(6):758-66. DOI: 10.1097/00000478-200206000-00009. View

15.

Chang H, Yoo B, Kim S, Lee B, Kim W . Significance of PML and p53 protein as molecular prognostic markers of gallbladder carcinomas. Pathol Oncol Res. 2007; 13(4):326-35. DOI: 10.1007/BF02940312. View

16.

Oxley da Rocha A, Barbosa Coutinho L, Scholl J, Leboutte L . The value of p53 protein expression in gallbladder carcinoma: analysis of 60 cases. Hepatogastroenterology. 2004; 51(59):1310-4. View

17.

Galizia G, Ferraraccio F, Lieto E, Orditura M, Castellano P, Imperatore V . Prognostic value of p27, p53, and vascular endothelial growth factor in Dukes A and B colon cancer patients undergoing potentially curative surgery. Dis Colon Rectum. 2004; 47(11):1904-14. DOI: 10.1007/s10350-004-0695-8. View

18.

Oohashi Y, Watanabe H, Ajioka Y, Hatakeyama K . p53 immunostaining distinguishes malignant from benign lesions of the gall-bladder. Pathol Int. 1995; 45(1):58-65. DOI: 10.1111/j.1440-1827.1995.tb03380.x. View

19.

Alkushi A, Lim P, Coldman A, Huntsman D, Miller D, Gilks C . Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level. Int J Gynecol Pathol. 2004; 23(2):129-37. DOI: 10.1097/00004347-200404000-00007. View

20.

Hirata K, Ajiki T, Okazaki T, Horiuchi H, Fujita T, Kuroda Y . Frequent occurrence of abnormal E-cadherin/beta-catenin protein expression in advanced gallbladder cancers and its association with decreased apoptosis. Oncology. 2007; 71(1-2):102-10. DOI: 10.1159/000100478. View